Vialafil XR 1350 mg
Withdrawn from the US market on 19 July 2024 (according to the DSLD)
NewtonEverett, food supplement from the US market
Label withdrawn from the US market. Vialafil XR 1350 mg (NewtonEverett), a food supplement au code-barres 689076027946, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Conditions légales
Lepidium meyenii Walp.: L'absence d'alcaloïdes doit être démontrée par des rapports d'analyse.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- NewtonEverett
- Barcode
- 689076027946
- Form
- Capsule
- One serving
- 2 capsules
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Gelatin, Vegetable Magnesium Stearate, Rice Flour, Silicon Dioxide, FD&C Blue #1 Lake, Titanium Dioxide
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Zinc | Mineral | 15 mg |
| Proprietary Blend | Blend | 1,350 mg |
| L-Arginine Hydrochloride | Amino acid | not stated |
| Epimedium sagittatum | Plant | not stated |
| Eleuthero extract (Eleutherococcus senticosus) | Plant | not stated |
| Maca extract (Lepidium meyenii) | Plant | not stated |
| Tongkat Ali (Eurycoma longifolia) | Plant | not stated |
| Xanthoparmelia scabrosa | Other | not stated |
| Oat Straw extract (Avena sativa) | Plant | not stated |
| Muira Puama extract (Ptychopetalum olacoides) | Plant | not stated |
| Ginkgo biloba extract | Plant | not stated |
| Cnidium (Cnidium monnieri) | Plant | not stated |
| Catuaba | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Vialafil XR 1500 mg
Entered into DSLD on 25 July 2014. Withdrawn from the US market on 19 July 2024 (according to the DSLD).- Active ingredient added : Avena sativa (quantity not stated)
- Active ingredient added : Catuaba 4:1 (quantity not stated)
- Active ingredient added : Cnidium monnier extract (quantity not stated)
- Active ingredient added : Epimedium extract (quantity not stated)
- Active ingredient added : Ginkgo biloba 24:6 (quantity not stated)
- Active ingredient added : Maca (quantity not stated)
- Active ingredient added : Muira Puama 4:1 (quantity not stated)
- Active ingredient added : Siberian Ginseng extract 35:1 (quantity not stated)
- Active ingredient added : Tongkat Ali LJ100 (quantity not stated)
- Active ingredient added : Xanthoparmelia Scabrosa extract 10:1 (quantity not stated)
- Active ingredient removed : Catuaba (quantity not stated)
- Active ingredient removed : Cnidium (quantity not stated)
- Active ingredient removed : Eleuthero extract (quantity not stated)
- Active ingredient removed : Epimedium sagittatum (quantity not stated)
- Active ingredient removed : Ginkgo biloba extract (quantity not stated)
- Active ingredient removed : Maca extract (quantity not stated)
- Active ingredient removed : Muira Puama extract (quantity not stated)
- Active ingredient removed : Oat Straw extract (quantity not stated)
- Active ingredient removed : Tongkat Ali (quantity not stated)
- Active ingredient removed : Xanthoparmelia scabrosa (quantity not stated)
- Different quantity per serving : Proprietary Blend: 1,500 mg in this version; 1,350 mg on the displayed label
Official label: Vialafil XR 1500 mg
Entered into DSLD on 25 July 2014. Withdrawn from the US market on 19 July 2024 (according to the DSLD).- Active ingredient added : Avena sativa (quantity not stated)
- Active ingredient added : Catuaba 4:1 (quantity not stated)
- Active ingredient added : Cnidium monnier extract (quantity not stated)
- Active ingredient added : Epimedium extract (quantity not stated)
- Active ingredient added : Ginkgo biloba 24:6 (quantity not stated)
- Active ingredient added : Maca (quantity not stated)
- Active ingredient added : Muira Puama 4:1 (quantity not stated)
- Active ingredient added : Siberian Ginseng extract 35:1 (quantity not stated)
- Active ingredient added : Tongkat Ali LJ100 (quantity not stated)
- Active ingredient added : Xanthoparmelia Scabrosa extract 10:1 (quantity not stated)
- Active ingredient removed : Catuaba (quantity not stated)
- Active ingredient removed : Cnidium (quantity not stated)
- Active ingredient removed : Eleuthero extract (quantity not stated)
- Active ingredient removed : Epimedium sagittatum (quantity not stated)
- Active ingredient removed : Ginkgo biloba extract (quantity not stated)
- Active ingredient removed : Maca extract (quantity not stated)
- Active ingredient removed : Muira Puama extract (quantity not stated)
- Active ingredient removed : Oat Straw extract (quantity not stated)
- Active ingredient removed : Tongkat Ali (quantity not stated)
- Active ingredient removed : Xanthoparmelia scabrosa (quantity not stated)
- Different quantity per serving : Proprietary Blend: 1,500 mg in this version; 1,350 mg on the displayed label
Official label: Vialafil XR 1500 mg
Entered into DSLD on 25 July 2014. Withdrawn from the US market on 19 July 2024 (according to the DSLD).- Active ingredient added : Avena sativa (quantity not stated)
- Active ingredient added : Cnidium monnier (quantity not stated)
- Active ingredient added : Epimedium extract (quantity not stated)
- Active ingredient added : Ginkgo biloba (quantity not stated)
- Active ingredient added : Maca (quantity not stated)
- Active ingredient added : Muira Puama (quantity not stated)
- Active ingredient added : Siberian Ginseng extract (quantity not stated)
- Active ingredient added : Tongkat Ali LJ100 (quantity not stated)
- Active ingredient added : Xanthoparmelia scabrosa extract (quantity not stated)
- Active ingredient removed : Cnidium (quantity not stated)
- Active ingredient removed : Eleuthero extract (quantity not stated)
- Active ingredient removed : Epimedium sagittatum (quantity not stated)
- Active ingredient removed : Ginkgo biloba extract (quantity not stated)
- Active ingredient removed : Maca extract (quantity not stated)
- Active ingredient removed : Muira Puama extract (quantity not stated)
- Active ingredient removed : Oat Straw extract (quantity not stated)
- Active ingredient removed : Tongkat Ali (quantity not stated)
- Active ingredient removed : Xanthoparmelia scabrosa (quantity not stated)
- Different quantity per serving : Proprietary Blend: 1,500 mg in this version; 1,350 mg on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Eleuthero extract
Read the warning, when it applies and the studies cited
ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS
Route of administration: Oral (ESCOP 2003; Bradley 1992)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
Contraindications
Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).
Sources cited by Health Canada (5)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
- Maca extract
Read the warning, when it applies and the studies cited
Maca - Lepidium Meyenii
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Applies to products providing 0.6 g or more dried root/hypocotyl, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).
Sources cited by Health Canada (1)
- Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Randomised trial
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).
Sources cited by Health Canada (2)
- Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomised trial
- Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed
Condition of application: Healthy mood balance; Sexual health.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).
Sources cited by Health Canada (3)
- Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Review article
- Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomised trial
- Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : NewtonEverett
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Vialafil XR 1350 mg : étiquette retirée du marché américain (NewtonEverett): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/689076027946-vialafil-xr-1350-mg-newtoneverett, updated 19 July 2024.